全文获取类型
收费全文 | 4003篇 |
免费 | 235篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 83篇 |
妇产科学 | 64篇 |
基础医学 | 607篇 |
口腔科学 | 137篇 |
临床医学 | 286篇 |
内科学 | 1030篇 |
皮肤病学 | 77篇 |
神经病学 | 283篇 |
特种医学 | 223篇 |
外科学 | 410篇 |
综合类 | 16篇 |
预防医学 | 231篇 |
眼科学 | 20篇 |
药学 | 260篇 |
中国医学 | 3篇 |
肿瘤学 | 503篇 |
出版年
2023年 | 24篇 |
2022年 | 31篇 |
2021年 | 70篇 |
2020年 | 58篇 |
2019年 | 86篇 |
2018年 | 121篇 |
2017年 | 72篇 |
2016年 | 82篇 |
2015年 | 75篇 |
2014年 | 134篇 |
2013年 | 193篇 |
2012年 | 326篇 |
2011年 | 286篇 |
2010年 | 156篇 |
2009年 | 157篇 |
2008年 | 256篇 |
2007年 | 269篇 |
2006年 | 254篇 |
2005年 | 253篇 |
2004年 | 249篇 |
2003年 | 209篇 |
2002年 | 172篇 |
2001年 | 65篇 |
2000年 | 58篇 |
1999年 | 53篇 |
1998年 | 46篇 |
1997年 | 41篇 |
1996年 | 31篇 |
1995年 | 36篇 |
1994年 | 22篇 |
1993年 | 32篇 |
1992年 | 48篇 |
1991年 | 30篇 |
1990年 | 39篇 |
1989年 | 32篇 |
1988年 | 12篇 |
1987年 | 22篇 |
1986年 | 14篇 |
1985年 | 13篇 |
1984年 | 17篇 |
1983年 | 12篇 |
1982年 | 13篇 |
1981年 | 13篇 |
1980年 | 5篇 |
1979年 | 14篇 |
1978年 | 6篇 |
1975年 | 4篇 |
1974年 | 6篇 |
1972年 | 6篇 |
1967年 | 4篇 |
排序方式: 共有4247条查询结果,搜索用时 31 毫秒
51.
José S A Belderbos Katrien De Jaeger Wilma D Heemsbergen Yvette Seppenwoolde Paul Baas Liesbeth J Boersma Joos V Lebesque 《Radiotherapy and oncology》2003,66(2):119-126
PURPOSE: To evaluate the feasibility of dose escalation in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiation therapy. PATIENTS AND METHODS: The main eligibility criteria of the trial were: pathologically proven inoperable NSCLC, ECOG performance status or=grade 3 (SWOG), grade 3 early and grade 2 late esophageal toxicity or any other (RTOG) grade 3 or 4 complications). RESULTS: Fifty-five patients were included. Tumor stage was I/II in 47%, IIIA in 33% and IIIB in 20%. The majority of the patients received a dose of 74.3 Gy (n=17) or 81.0 Gy (n=23). Radiation pneumonitis occurred in seven patients: four patients developed a grade 2, two patients grade 3 and one patient a grade 4. Esophageal toxicity was mild. In 50 patients tumor response at 3 months follow-up was evaluable. In six patients a complete response was recorded, in 38 a partial response, five patients had stable disease and one patient experienced progressive disease. Only one patient developed an isolated failure in an uninvolved nodal area. So far the radiation dose was safely escalated to 87.8 Gy in group 1 (lowest rMLD), 81.0 Gy in groups 2 and 3 and 74.3 Gy in group 4. CONCLUSION: Three-dimensional conformal radiotherapy enables significant dose escalation in NSCLC. The maximum tolerable dose has not yet been reached in any risk group. 相似文献
52.
Cornelis P. J. Vendrik Anne Marie J. Fichtinger-Schepman Wilhelmina C. M. van Dijk-Knijnenburg W. H. de Jong Anke C. E. van der Minnen Gerard de Groot Geert Frits Berends P. A. Steerenberg 《Cancer chemotherapy and pharmacology》1997,39(6):479-485
An IgM immunocytoma cell line sensitive to cis-diamminedichloroplatinum(II) (CDDP) and a subline with acquired resistance were grown in LOU/M rats. In a previous study
with such rats that had been treated with a high dose of CDDP (10 mg/kg) the tumors did not show differences in cellular platinum
content or DNA-adduct levels, either immediately after treatment or 24 h later. Recently, this high dose was found to overcome
resistance. Therefore, the study was repeated with a 10-fold lower dose (1 mg/kg, i.v.). At 1 and 24 h after treatment, tumor
and kidney tissue were assayed for cellular platinum (atomic absorption spectroscopy, AAS) and DNA platination (immunochemical
detection of the four CDDP-DNA adducts). The results were compared with previous data. All tissues showed a linear response
to dose with regard to platinum uptake as well as adduct formation, with no quantitative difference being seen between the
tumors. Also the relative occurrence of the four adducts was very similar. Between 1 and 24 h, in tumors a substantial decrease
occurred in both platinum content and adduct level; the kidneys showed little reduction, if any. At the lower CDDP dose a
somewhat larger loss of platinum and removal of DNA adducts was observed for the resistant tumor, but these differences could
be explained by “dilution”, as this tumor continues to grow after low-dose treatment (about 20% within 24 h). Since the strong
difference observed between the tumors in sensitivity to CDDP cannot be attributed to differences in CDDP uptake, efficiency
of adduct formation, or repair capability, other mechanisms are held responsible.
Received 10 August 1995 / Accepted: 14 August 1996 相似文献
53.
H. Burger K. Nooter A. W. Boersma C. J. Kortland G. Stoter 《British journal of cancer》1998,77(10):1562-1567
We examined the sensitivity for cisplatin-induced apoptosis in a panel of four testicular germ cell tumour (TGCT) cell lines and monitored the cellular expression of the apoptosis-related proteins p53, Bcl-2 and Bax. Three of four TGCT cell lines (NT2, NCCIT and S2) were hypersensitive for cisplatin-induced apoptosis, while the TGCT cell line 2102 EP appeared to be resistant for cisplatin-induced apoptosis, even at relatively high drug concentrations (12.5 microM). For all four cell lines, the induction of apoptosis by cisplatin correlated with drug sensitivity in the MTT assay. The differences in chemosensitivity and induction of apoptosis could not be attributed to differences in cellular platinum accumulation, DNA platination or platinum-DNA adduct removal. We next analysed the relationship between p53 status and cisplatin-induced up-regulation of p53, and the susceptibility to cisplatin-induced apoptosis. Wild-type p53 containing NT2 and 2102 EP cells showed p53 up-regulation upon drug treatment, and NCCIT (mutant p53) and S2 (no p53 protein) cells did not. Consistently, the increase in wild-type p53 protein in NT2 and 2102 EP cells led to an increase in mRNA level of the p53 downstream gene p21/WAF/CIP, whereas mutant p53-containing NCCIT cells and p53-non-expressing S2 cells could not transactivate this p53-responsive gene. As NT2, NCCIT and S2 were readily triggered into apoptosis, while 2102 EP cells failed to undergo cisplatin-induced apoptosis, our data suggest that the presence of wild-type and/or transactivation-competent p53 might not be an absolute prerequisite for efficient induction of apoptosis in TGCT cell lines. Also endogenous levels of Bcl-2 and Bax expression did not correlate with cisplatin-induced apoptosis. In addition, the endogenous Bcl-2 and Bax expression was not affected by cisplatin treatment. The present study suggests that, at least in our panel of TGCT cell lines, hypersensitivity for cisplatin-induced apoptosis might not be necessarily correlated with the presence of wild-type p53 and is probably not associated with Bcl-2 and Bax expression. 相似文献
54.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
55.
David Q Liu Bindhu V Karanam George A Doss Rick R Sidler Stella H Vincent Cornelis E C A Hop 《Drug metabolism and disposition》2004,32(9):1023-1031
The in vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide], a novel 2,4-thiazolidinedione (TZD)-containing peroxisome proliferator-activated receptor alpha/gamma agonist, was studied in rat, dog, monkey, and human liver microsomes and hepatocytes, as well as in recombinant human CYP3A4-containing microsomes. Twenty-two metabolites (some at trace levels) were detected by liquid chromatography-tandem mass spectrometry analysis. All appeared to be phase I metabolites except for a glucuronide conjugate of a hydroxylated metabolite that was detected at trace levels. A constant neutral loss scan experiment performed on a triple quadrupole mass spectrometer proved to be very useful for resolving the metabolites from endogenous compounds. It was observed that the initial site of metabolism of MK-0767 was at the TZD ring leading to two major metabolites, namely the 5-hydroxy-TZD metabolite (M24) and the mercapto metabolite (M22). The latter was formed via the cleavage of the TZD ring with the elimination of the carbonyl adjacent to the sulfur atom. The structure of M24 was established by accurate mass measurements and NMR analysis. This hydroxy-TZD metabolite might represent an important precursor for a group of metabolites formed by TZD ring opening and subsequent loss of the sulfur moiety. The mercapto metabolite, on the other hand, is probably the key precursor for the TZD ring-opened metabolites with retention of the sulfur, even though the detailed mechanism of the ring scission remains to be characterized. From these studies, it was concluded that the TZD ring was the major site of metabolism of MK-0767. All the metabolites produced in vitro from human preparations were detected in the corresponding preparations from the nonclinical species. 相似文献
56.
Implementation of the Veder contact method in daily nursing home care for people with dementia: a process analysis according to the RE‐AIM framework 下载免费PDF全文
57.
58.
59.
60.
Mauro Loi Michael Frelinghuysen Natalie Desiree Klass Esther Oomen-De Hoop Patrick Vincent Granton Joachim Aerts Cornelis Verhoef Joost Nuyttens 《Clinical & experimental metastasis》2018,35(7):625-633
Stereotactic body radiotherapy (SBRT) has emerged as an effective option in oligo-metastatic cancer patients affected by lymph node metastases, but its use might be questioned due to risk of regional and distant dissemination through the lymph node chain. The primary aim of our study was to assess the loco-regional control following SBRT in this setting. Ninety-one patients undergoing SBRT for at least one lymph node metastasis from miscellaneous primary tumors were retrospectively evaluated for patterns of failure and toxicity. locoregional relapse-free survival (LRRFS) and distant metastasis-free survival (DMFS) at 4 years were 79 and 44%. Repeated use of local therapy after progression resulted in a median interval of 17 months until allocation to systemic therapy or supportive care. Forty-three percent of patients were alive at 4 years. Local failure, occurring in 15% of patients, was the only predictor of poor survival (HR: 3.06). Tumor diameter?≥?30 mm and urothelial primary tumor predicted for impaired local control (HR: 4.59 and 5.43, respectively). Metastases from pulmonary cancer showed a significant earlier distant dissemination (HR: 3.53). Only acute and late grade 1–2 toxicities were reported except for 1 case of G3 dysphagia. Loco-regional failure risk is low (18%) and justifies the use of local therapies for patients with oligometastatic disease. Durable disease remission can be achieved by iterative use of local approaches. Local control is correlated to improved OS. Diameter and primary tumor type may affect response to SBRT and risk for early metastatic dissemination. 相似文献